Holen Sie sich die Stockscreener-App
84.37
0.27%
0.23
Vorhandelsmarkt:
86.64
2.27
+2.69%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$84.14
Offen:
$84.55
24-Stunden-Volumen:
1.00M
Relative Volume:
1.20
Marktkapitalisierung:
$41.73B
Einnahmen:
$9.76B
Nettoeinkommen (Verlust:
$1.16B
KGV:
36.06
EPS:
2.34
Netto-Cashflow:
$665.00M
1W Leistung:
+1.15%
1M Leistung:
-1.37%
6M Leistung:
-6.26%
1J Leistung:
+10.36%
1-Tages-Spanne:
$84.26
$84.80
1-Wochen-Bereich:
$82.31
$84.80
52-Wochen-Spanne:
$74.30
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
84.37 | 41.73B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
592.64 | 211.09B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
237.38 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
RMD
Resmed Inc
|
239.78 | 35.23B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
336.34 | 24.40B | 2.88B | 499.60M | 321.60M | 6.74 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study - AWS Blog
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study | AWS - AWS Blog
Alcon to Seek M&A - Marketscreener.com
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Redburn raises Alcon stock rating to Buy By Investing.com - Investing.com Nigeria
Redburn raises Alcon stock rating to Buy - Investing.com
Dry Eye Disease Market Is Booming Worldwide 2025-2032 | Novartis - openPR
Alcon Inc. (VTX:ALC) is favoured by institutional owners who hold 63% of the company - Simply Wall St
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
Alcon recalls Systane eye drops due to potential fungal contamination risk - WRAL News
Alcon Laboratories Recalls Systane Eye Drops Over Fungal Risk - Franklin County Free Press
Alcon Labs Recalls Systane Lubricant Eye Drops Over Fungal Contamination - Nasdaq
Refractive Surgery Market Growth in Future Scope 2024-2031 | - openPR
Retinal Laser Photocoagulation Market Top PlayersAlcon, A.R.C Laser, Ellex Medical, Carl Zeiss, Quantel Medical. - openPR
Here's Why Alcon (ALC) is a Strong Growth Stock - MSN
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - GlobeNewswire
Alcon Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), Due to Fungal Contamination - US Recall News
Alcon a top pick for 2025 at Needham on upcoming product launches - MSN
Alcon Top Pick for 2025 at Needham, added to Conviction List - MSN
Alcon stock named top pick for 2025 by Needham, positive on margin and earnings growth - Investing.com Australia
RSI Alert: Alcon (ALC) Now Oversold - Nasdaq
Reasons to Retain Alcon Stock in Your Portfolio for Now - MSN
Does Alcon (VTX:ALC) Have A Healthy Balance Sheet? - Simply Wall St
Alcon Loses Bid To Patent Improved Eye Drug At EPO - Law360
Alcon to lay off dozens of food service workers at Fort Worth campus on Christmas Eve - Yahoo! Voices
Why Alcon (ALC) is a Top Growth Stock for the Long-Term - Yahoo Finance
Alcon Inc. (ALC): A Bull Case Theory - MSN
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart
Photobiomodulation Market Overall Study Report 2024-2031 | - openPR
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):